Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.